Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer.
Saved in:
| Title: | Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer. |
|---|---|
| Authors: | Pollin G; The RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Lomberk GA; The RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Mathison AJ; The RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Zimmermann MT; The RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Urrutia R; The RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. |
| Source: | Journal of gastrointestinal oncology [J Gastrointest Oncol] 2024 Aug 31; Vol. 15 (4), pp. 1996-2001. Date of Electronic Publication: 2024 Aug 01. |
| Publication Type: | Editorial; Comment |
| Journal Info: | Publisher: AME Publishing Group Country of Publication: China NLM ID: 101557751 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2078-6891 (Print) Linking ISSN: 20786891 NLM ISO Abbreviation: J Gastrointest Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
